SPIA
TGTX icon

Steward Partners Investment Advisory’s TG Therapeutics TGTX Stock Holding History

Steward Partners Investment Advisory’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,045
Closed -$94.6K – 4095
2024
Q3 		$94.6K Buy
+4,045
New +$88.3K ﹤0.01% 1902
2024
Q2 		– Sell
-250
Closed -$3.8K – 3716
2024
Q1 		$3.8K Hold
250
– – ﹤0.01% 3126
2023
Q4 		$4.27K Hold
250
– – ﹤0.01% 3024
2023
Q3 		$2.09K Hold
250
– – ﹤0.01% 3076
2023
Q2 		$6.21K Hold
250
– – ﹤0.01% 2726
2023
Q1 		$3.76K Hold
250
– – ﹤0.01% 2874
2022
Q4 		$2.96K Buy
+250
New +$1.81K ﹤0.01% 2932
2021
Q2 		– Sell
-1,000
Closed -$48.2K – 7391
2021
Q1 		$48.2K Buy
+1,000
New +$48K ﹤0.01% 2004

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Steward Partners Investment Advisory's TGTX Position: Q4 2024 in Review

Steward Partners Investment Advisory sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 4,045 shares — an estimated $94.6K sold.

Steward Partners Investment Advisory first reported a position in TGTX in Q1 2021 and held it in 8 quarters. The position peaked at $94.6K in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Steward Partners Investment Advisory reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 4,045 TG Therapeutics shares in Q4 2024, an estimated $94.6K.
  • Steward Partners Investment Advisory first reported a position in TG Therapeutics in Q1 2021 and held it in 8 quarters.
  • Steward Partners Investment Advisory's TG Therapeutics position peaked at $94.6K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2024, filed 6 Feb 2025.